Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011

Abstract

BackgroundSurrogate endpoint trials test strategies more efficiently but are accompanied by uncertainty about the relationship between changes in surrogate markers and clinical outcomes.Methods and ResultsWe identified cardiovascular trials with primary surrogate endpoints published in the New England Journal of Medicine, Lancet, and JAMA: Journal of the American Medical Association from 1990 to 2011 and determined the trends in publication of surrogate endpoint trials and the success of the trials in meeting their primary endpoints. We tracked for publication of clinical outcome trials on the interventions tested in surrogate trials. We screened 3016 articles and identified 220 surrogate endpoint trials. From the total of 220 surrogate trials, 157 (71.4%) were positive for their primary endpoint. Only 59 (26.8%) surrogate trials had a subsequent clinical outcomes trial. Among these 59 trials, 24 outcomes trial results validated the positive surrogates, whereas 20 subsequent outcome trials were negative following positive results on a surrogate. We identified only 3 examples in which the surrogate trial was negative but a subsequent outcomes trial was conducted and showed benefit. Findings were consistent in a sample cohort of 383 screened articles inclusive of 37 surrogate endpoint trials from 6 other high‐impact journals.ConclusionsAlthough cardiovascular surrogate outcomes trials frequently show superiority of the tested intervention, they are infrequently followed by a prominent outcomes trial. When there was a high‐profile clinical outcomes study, nearly half of the positive surrogate trials were not validated. Cardiovascular surrogate outcome trials may be more appropriate for excluding benefit from the patient perspective than for identifying it.

Healing an ailing pharmaceutical system: prescription for reform for United States and Canada

“…For instance, trials have compared new agents with placebos rather than the best existing therapies, underdosed comparator drugs, or relied on surrogate endpoints65 that may not predict outcomes. Some commercially funded researchers have also selectively published (and republished) positive results 866 or concealed negative findings,67 while firms have ended trials prematurely for purely commercial reasons 68…”

MicroRNAs' Gene Expression Technology for the Evaluation of Disease Modulation by Mild Nutrients

“…A biomarker is believed to be a characteristic indicator of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic interventions [10,11]. In contrast, clinical endpoints are considered as variables representing a study subject's health from his/her perspective [12][13][14][15][16][17][18][19][20][21][22]. A variety of biomarkers exist today as surrogates to access clinical outcomes in diseases, predict the health of individuals, or improve drug development.…”

Warning About Shortcuts in Drug Development

“…In this issue of JAHA , Bikdeli et al provide documentation from an examination of the literature that shows that building cardiovascular clinical therapeutics from trials based solely on unvalidated biomarkers would be folly . The authors extracted information from 3 prominent medical journals, focusing on clinical trials that used biomarkers as primary outcome measures.…”

“…In this issue of JAHA, Bikdeli et al provide documentation from an examination of the literature that shows that building cardiovascular clinical therapeutics from trials based solely on unvalidated biomarkers would be folly. 2 The authors extracted information from 3 prominent medical journals, focusing on clinical trials that used biomarkers as primary outcome measures. As previous reports would suggest, they found that the majority of these studies either were not followed by trials measuring a clinical outcome as a primary endpoint, or, when such trials were done, they found that the positive biomarker findings were not associated with better clinical outcomes.…”